Home|Journals|Articles by Year|Audio Abstracts

Original Article

J App Pharm Sci. 2017; 7(8): 104-115

Inulin nanoparticles and silymarin counteract chlorpromazine-induced injury in the liver and kidney of rats

Mosaad A. Abdel-Wahhab, Nihad I. Eid, Lamiaa A. Ahmed, Ghada M. Ragab, Aziza A. El-Nekeety, Mohamed M. El-Hakim, Nabila S. Hassan.


The aim of the current study was to evaluate the protective role of inulin nanoparticles (INPs) prepared by the emulsion method alone or plus silymarin (SIL) against chlorpromazine (CPZ)-induced hepatonephrotoxicity in rats. Eleven female Sprague-Dawley rats were treated orally for 3 weeks as follow: control group, the group treated with CPZ (38.7 mg/kg. b.w in 1 ml saline each 72 h), the groups treated with INPs at low (100 mg/kg b.w) or high (200 mg/ kg b.w) dose, the group treated with SIL (50 mg/kg b.w), the groups treated with SIL plus INPs at the tow doses and the groups treated with CPZ plus SIL and INPs at the tow tested doses. At the end of treatment period, blood and tissue samples were collected for different biochemical and histological analyses. The results indicated that CPZ induced significant disturbances in liver and kidney function indices, oxidative stress markers, lipid profile, antioxidant enzymes activity and DNNA fragmentation as well as histological changes in liver and kidney. SIL alone or plus INPs alone at the low or high doses did not induce any significant changes in all the tested parameters of histological picture of the liver and kidney. SIL and INPs at the tow tested doses succeeded to induce a significant protection against CPZ-induce hepatonephrotoxicity due to their antioxidant activity and the role of INPs in enhancement the solubility of SIL. It could be concluded that INPs is a promise drug delivery and could prevent the liver and kidney injury induced by CPZ.

Key words: Chlorpromazine; Inulin naopartices; silymarin; liver; kidney; oxidative stress

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.